A vaccine that will be available soon to the general public in the United States is being developed by the US Centers for Disease Control and Prevention, according to the agency.

The vaccine was developed by Gilead Sciences Inc, a subsidiary of the drugmaker, the agency announced Tuesday.

It said the vaccine is designed to help protect people with Ebola who have not yet recovered from the virus.

A vaccine will be approved for the United Nations Population Fund’s (UNFPA) flagship programme to fight the Ebola virus, which has killed about 1,400 people and infected 1,500 since it began in West Africa in March.

The US is currently one of just a handful of countries that do not have a vaccine for Ebola.

The United States was the only country to offer the vaccine before its outbreak, and the United Kingdom has not yet received one.

Gileady has also developed a similar vaccine, and it is not expected to go into clinical trials until at least 2020, the US agency said.

GilderLab announced in November that it had developed a vaccine designed to treat people with the Ebola strain that infected Americans in Liberia and Sierra Leone.

It had said it would use the vaccine developed by GlaxoSmithKline and another by Novartis AG.

The vaccines, which will be manufactured in Gildersmith, Pennsylvania, are similar to the experimental Ebola vaccine that has been used by the UK National Institute for Health Research.

GILDA’S COOPERATION WITH UK ON COVID CONTROL Gildercare, a leading maker of oral antiretroviral drugs, is part of a consortium of companies and universities that is working with UK authorities to help to develop a vaccine to treat the Ebola outbreak.

The drug company said in October that it has signed a deal with the UK government to work with the Ministry of Health on a vaccine.

The UK has pledged to provide Gilderta with a stockpile of vaccine materials, which it has yet to do.

The company said that it is working closely with Gildera and other partners to ensure that the vaccine works well in a range of settings, including at home, in schools and in healthcare settings.

The new vaccine is expected to be available to patients by the end of this year.

The Gildernews news site also reported on Tuesday that the UK will use a new technology to detect the virus in the saliva of Ebola patients.

The researchers at the University of Cambridge, who developed the technology, said they had successfully developed a way to detect Ebola in the blood of Ebola victims.

The virus can survive in saliva for weeks, so it is a very sensitive test.

The team said the test will not only detect the Ebola RNA in saliva, but also in the proteins that control the virus’ ability to replicate.

The testing will allow healthcare workers to screen for Ebola patients who may be carrying the virus and to quickly isolate and treat those who may have recovered from infection.

The technology was developed as part of the UK’s £10 million Ebola research programme, which was launched last year.

It is being used in the US and the European Union to develop vaccines and other treatments for the virus that have been shown to be effective in clinical trials.